Free Consultation
Leave a request and our pharmacist will help answer your questions
Munjaro –
A novel dual-mechanism tirzepatide-based drug for the treatment of type 2 diabetes and obesity
The cost of the medication
Eli Lilly’s original innovative drug
The company is known for its innovations, including in the field of diabetes treatment. Mounjaro is one of the latest innovative drugs from Eli Lilly. It was approved by the FDA in 2022 for use in patients with type 2 diabetes to control blood sugar levels
Eli Lilly and Company, an American pharmaceutical company founded in 1876, is a leading global manufacturer of medicines, with a broad portfolio of drugs used to treat a wide range of diseases
Decreased appetite
It mimics the action of the GLP-1 hormone, which signals satiety
What functions does it perform?
Creating a feeling of fullness
It slows gastric emptying, providing a longer-lasting feeling of fullness. You feel full even after eating less
Stimulates insulin production
Helps regulate blood glucose levels and reduces hunger
Metabolic change
Influence metabolism, promoting more efficient use of fat as an energy source
What functions does it perform?
Consult your doctor before taking Mounjaro
Contraindications
- Hypersensitivity to tirzepatide or any excipient of Mounjaro, or container components.
- Personal or family history of medullary thyroid carcinoma.
- Multiple endocrine neoplasia type 2 (MEN2) syndrome.
- Type 1 diabetes mellitus.
- Acute pancreatitis.
- Pregnancy.
- Breastfeeding.
- Age under 18 years
Important!
Contraindications
The medication is generally well-tolerated, with a low risk of side effects
- Nausea, vomiting, diarrhea
- Headache, fatigue
- Hypoglycemia (low blood sugar)
- Rash, itching
- Taste changes
The most common side effects are:
The medication is well-tolerated
It’s the first drug to mimic the action of two naturally occurring hormones: GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory polypeptide)
How does a tirzepatide-based drug work?
It’s the first drug to mimic the action of two naturally occurring hormones: GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory polypeptide)
How does a tirzepatide-based drug work?
Decreased appetite
It mimics the action of the GLP-1 hormone, which signals satiety
Creating a feeling of fullness
It slows gastric emptying, providing a longer-lasting feeling of fullness. You feel full even after eating less
Stimulates insulin production
Helps regulate blood glucose levels and reduces hunger
Metabolic change
Influence metabolism, promoting more efficient use of fat as an energy source
What functions does it perform?
Contraindications
Consult your doctor before taking Mounjaro
- Hypersensitivity to tirzepatide or any excipient of Mounjaro, or container components.
- Personal or family history of medullary thyroid carcinoma.
- Multiple endocrine neoplasia type 2 (MEN2) syndrome.
- Type 1 diabetes mellitus.
- Acute pancreatitis.
- Pregnancy.
- Breastfeeding.
- Age under 18 years
Important!
The medication is generally well-tolerated, with a low risk of side effects
The most common side effects are:
- Nausea, vomiting, diarrhea
- Headache, fatigue
- Hypoglycemia (low blood sugar)
- Rash, itching
- Taste changes
Decreased appetite
It mimics the action of the GLP-1 hormone, which signals satiety
Creating a feeling of fullness
It slows gastric emptying, providing a longer-lasting feeling of fullness. You feel full even after eating less
Stimulates insulin production
Helps regulate blood glucose levels and reduces hunger
Metabolic change
Influence metabolism, promoting more efficient use of fat as an energy source
What functions does it perform?
Contraindications
Consult your doctor before taking Mounjaro
- Hypersensitivity to tirzepatide or any excipient of Mounjaro, or container components.
- Personal or family history of medullary thyroid carcinoma.
- Multiple endocrine neoplasia type 2 (MEN2) syndrome.
- Type 1 diabetes mellitus.
- Acute pancreatitis.
- Pregnancy.
- Breastfeeding.
- Age under 18 years
Important!
The medication is generally well-tolerated, with a low risk of side effects
The most common side effects are:
- Nausea, vomiting, diarrhea
- Headache, fatigue
- Hypoglycemia (low blood sugar)
- Rash, itching
- Taste changes
Side effect
The most frequently reported adverse reactions in clinical trials were gastrointestinal disorders, including nausea, diarrhea, and vomiting. In general, these reactions were mild to moderate in severity. Adverse reactions from the gastrointestinal tract (4.2%) were the most common reasons for discontinuation of treatment. Adverse reactions during clinical trials These adverse reactions occurred more often with the use of the drug Munjaro than with the use of placebo. Metabolic and nutritional disorders: hypoglycemia, including severe hypoglycemia (in combination with basal insulin), decreased appetite. Hypoglycemia was more frequent when Munjaro was used in combination with sulfonylureas or basal insulin. From the gastrointestinal tract: nausea, diarrhea, vomiting, dyspepsia, constipation, abdominal pain, bloating, belching, flatulence, gastroesophageal reflux disease, acute cholecystitis, pancreatitis. In clinical trials, treatment with tirzepatide resulted in an average increase in pancreatic amylase levels by 33-38% and lipase by 31-42% compared to baseline. General disorders and reactions at the injection site: fatigue, tachycardia, weight loss, reaction at the injection site. Hypersensitivity reactions: urticaria, eczema. Immunogenicity In seven phase 3 clinical trials, 2570 (51.1%) patients treated with Munjaro had antibodies to tirzepatide (ADA). Of the 2,570 patients treated with Munjaro who had ADA, 94 (1.9%) and 107 (2.1%) had neutralizing antibodies against GIP and GLP-1 receptors, respectively, and 43 (0.9%) and 18 (0.4%) had neutralizing antibodies against native GIP and GLP-1, accordingly. There was no evidence of changes in the pharmacokinetic profile or effects on efficacy and safety associated with the development of ADAs. Hypersensitivity reactions Hypersensitivity reactions, sometimes severe, have been reported in clinical trials of the drug Munjaro. In the pool of placebo-controlled studies, hypersensitivity reactions were reported in 3.2% of patients treated with Munjaro, compared with 1.7% of patients treated with placebo. In a pool of seven clinical trials, hypersensitivity reactions occurred in 106/2570 (4.1%) Munjaro-treated patients with antithyrzepatide antibodies and in 73/2455 (3%) Munjaro-treated patients who did not develop antithyrzepatide antibodies. Reactions at the injection site In the pool of placebo-controlled studies, injection site reactions were reported in 3.2% of patients treated with Munjaro, compared with 0.4% of patients treated with placebo. In a pool of seven clinical trials, injection site reactions were observed in 119/2570 (4.6%) Munjaro-treated patients with antithyrzepatide antibodies and in 18/2455 (0.7%) Munjaro-treated patients in whom antithyrzepatide antibodies were not produced. The following serious adverse reactions have been described: the risk of C-cell thyroid tumors, complications of diabetic retinopathy, and renal failure. If you experience unpleasant symptoms or side effects, including symptoms or side effects that are not listed here, tell your doctor.
Studies show that the drug promotes weight loss averaging 15−23 kg from baseline weight
Truveta Research —
The analysis included data from 18,000 adults with overweight or obesity. The study showed that patients taking Mounjaro were three times more likely to lose 15% of their weight than those taking Ozempic. Furthermore, patients taking the Eli Lilly drug were 2.6 times more likely to lose 10% of their weight and 1.8 times more likely to lose 5% of their weight
18,000 people participated
Lost 15% weight 3x more often
In the SURMOUNT-1 study —
The SURMOUNT-1 study included 2539 participants with obesity and without diabetes. After 72 weeks, patients taking tirzepatide lost between 5.87 and 23.5 kg and experienced improved health. Weight loss depended on the dosage. Patients taking the placebo lost an average of only 2.26 kg
2,539 people participated
Lost 5.87-23.5 kg in 72 weeks
Patient reviews from the well-known website drugs.com
Nimrod
Taken for 1 to 6 months
315-pound man, 64 heavy drinker, quit all booze, gained weight. Began rowing machine daily, gained weight. Counted all calories, 2500/day, no loss. A1C not bad 7, went on Mounjaro lowest dose 2.5. Have lost 40 pounds (!) in two months, eat anything and everything just way less and no desire to snack between. Still losing a bit, but feel plateau, may ask for larger dose. A miracle, has changed my life mentally and physically.
Senagal
Taken for 1 to 6 months
I am an African American female, 58 years old, 5’8” tall, weighed an unbelievable 270 lbs on 12/30/22. I asked my doctor if I could take this medication, and now here we are, 8 weeks later. I currently weigh 244.6 lbs. I lost 16 lbs in the first 3 weeks. I was extremely shocked and a little worried. My health is a constant concern, I suffer from chronic allergies, and frequently took steroid shots to manage the problem, which brought on weight gain.
Ava
Taken for 1 to 6 months
I have learned to manage side effects (constipation) with probiotics. This is the only thing that has allowed me to lose the weight I gained post-menopause. I was a size 22 and am now almost a size 10. My BMI went from 39 to just over 30, and I have about 25 more pounds to go. I lost 45 pounds currently. I am no longer taking medication for migraines, asthma, and chronic edema, and my BP medication has been reduced by half.
Mika
Taken for 1 to 6 months
So far I have been on Mounjaro for a little short of two months. I started at 404 lbs and currently weigh 345 lbs. I've been on 5mg and will move to 7.5 mg after the last shot of 5mg. This has been an absolute game-changer for me. I did make the necessary changes though for the first time in my life. I'm working out 3-4 times a week and I've drastically changed my diet as well. Did blood work and everything is looking great. I didn't get the $25 coupon
Nimrod
Taken for 1 to 6 months
315-pound man, 64 heavy drinker, quit all booze, gained weight. Began rowing machine daily, gained weight. Counted all calories, 2500/day, no loss. A1C not bad 7, went on Mounjaro lowest dose 2.5. Have lost 40 pounds (!) in two months, eat anything and everything just way less and no desire to snack between. Still losing a bit, but feel plateau, may ask for larger dose. A miracle, has changed my life mentally and physically.
Senagal
Taken for 1 to 6 months
I am an African American female, 58 years old, 5’8” tall, weighed an unbelievable 270 lbs on 12/30/22. I asked my doctor if I could take this medication, and now here we are, 8 weeks later. I currently weigh 244.6 lbs. I lost 16 lbs in the first 3 weeks. I was extremely shocked and a little worried. My health is a constant concern, I suffer from chronic allergies, and frequently took steroid shots to manage the problem, which brought on weight gain.
Ava
Taken for 1 to 6 months
I have learned to manage side effects (constipation) with probiotics. This is the only thing that has allowed me to lose the weight I gained post-menopause. I was a size 22 and am now almost a size 10. My BMI went from 39 to just over 30, and I have about 25 more pounds to go. I lost 45 pounds currently. I am no longer taking medication for migraines, asthma, and chronic edema, and my BP medication has been reduced by half.
Mika
Taken for 1 to 6 months
So far I have been on Mounjaro for a little short of two months. I started at 404 lbs and currently weigh 345 lbs. I've been on 5mg and will move to 7.5 mg after the last shot of 5mg. This has been an absolute game-changer for me. I did make the necessary changes though for the first time in my life. I'm working out 3-4 times a week and I've drastically changed my diet as well. Did blood work and everything is looking great. I didn't get the $25 coupon